Maze Therapeutics (MAZE) CFO receives 40,000 options and 20,000 RSUs

Rhea-AI Filing Summary

Tahir Misbah reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that Chief Financial Officer Tahir Misbah received equity awards consisting of a stock option for 40,000 shares and 20,000 restricted stock units, both granted at a price of $0.00 per share.

The option award vests monthly in 1/48 increments, with the first portion vesting on April 1, 2026, as long as he continues serving the company. The restricted stock units vest in four equal annual installments, starting on March 1, 2027, with each unit representing the right to receive one share of common stock when it settles. These RSUs either vest or are cancelled before vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tahir Misbah

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$45.61	03/02/2026		A		40,000		(1)	03/01/2036	Common Stock	40,000	$0	40,000	D
Restricted Stock Units	(2)	03/02/2026		A		20,000		(3)	(4)	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

3. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

4. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Maze Therapeutics (MAZE) grant to its CFO?

Maze Therapeutics granted its CFO a stock option for 40,000 shares and 20,000 restricted stock units at a price of $0.00 per share. These awards provide long-term equity incentives, subject to time-based vesting and continued service conditions over several years.

How do Tahir Misbah’s stock options at Maze Therapeutics vest?

The 40,000-share stock option vests in 1/48 monthly increments, with the first tranche vesting on April 1, 2026. Continued service to Maze Therapeutics is required on each vesting date, aligning compensation with long-term employment and company performance over a four-year period.

What is the vesting schedule for Maze Therapeutics’ restricted stock units granted to the CFO?

The 20,000 restricted stock units vest in four equal annual installments of 1/4 each. The first tranche vests on March 1, 2027, with additional tranches vesting on each one-year anniversary, contingent on the CFO’s continued service to Maze Therapeutics on each vesting date.

What does each restricted stock unit represent in the Maze Therapeutics CFO grant?

Each restricted stock unit represents a contingent right to receive one share of Maze Therapeutics’ common stock upon settlement. The units do not have an expiration date; instead, they either vest according to the schedule or are cancelled before vesting if conditions are not met.

Does the Maze Therapeutics CFO Form 4 show any stock sales?

The Form 4 shows only equity award acquisitions, with two transactions coded as grants or awards. Both the stock options and restricted stock units were acquired at a price of $0.00 per share, and there are no reported sales or disposals in this filing.

What ownership type is reported for the Maze Therapeutics CFO’s new equity awards?

The filing reports the CFO’s newly granted stock options and restricted stock units as held with direct ownership. After these transactions, the total reported holdings are 40,000 stock options and 20,000 restricted stock units, all categorized as directly owned equity interests.